for designing antitumor agents. Herein, a novel class of nitric oxide donating cucurbitacin inspired estrone analogs (NO-CIEAs) were designed and synthesized as multitarget agents. Synthesized analogs were initially evaluated for their anti-hepatocellular carcinoma activities. Among the tested analogs, NO-CIEAs 17 and 20a exhibited more potent activity against HepG2 cells (IC50 = 4.69 and 12.5 µM, respectively)
杂交药物候选物的开发是设计抗肿瘤剂的众所周知的策略。在本文中,设计并合成了一类新的
一氧化氮供体
葫芦素激发的雌
酮类似物(NO-CIEAs),并将其合成为多靶点药物。首先评估合成的类似物的抗肝细胞癌活性。在测试的类似物中,NO-CIEA 17和20a的抗HepG2细胞活性(分别为IC50 = 4.69和12.5 µM)比参比药物
厄洛替尼(IC50 = 25 µM)更强。有趣的是,NO-CIEA 17还对耐
厄洛替尼的HepG2
细胞系(HepG2-R)(IC50 = 8.21 µM)发挥了强大的活性,从而使人们对其在耐药性治疗中的重要性有了更深入的了解。细胞内NO的测定表明,与参考前药JS-K相比,孵育1 h后,NO-CIEA 17和20a在肿瘤细胞中显示出NO产生的显着增加。流式细胞仪分析表明,NO-CIEA 17和20a均主要将HepG2细胞阻滞在G0 / G1期。同样,基于细胞内的ELI
SA筛选显示,NO-CIEA